FDA Accepts Eisai's Filing of LEQEMBI ® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease June 10, 2024 by True Academy Comments are off Posted in:Stock Market & Investment NewsTagged with:Buy Sell ShareFTSEKLCIMalaysiaPelaburanSahamShare Trading See more Prev:Far-right advances in EU election, France calls snap national vote Back: All Posts Next:US futures flat with inflation, Fed meeting on tap